normative

Rare Disease Trials Need Early-Evidence Approvals

For diseases with too few patients or very slow progression to test in standard trials, regulators should approve drugs based on mechanistic reasoning, animal data, early human testing, and preliminary biomarker evidence, then collect more rigorous data after market launch.

normativepending

Speaker

Alex

Evidence Quote

“we're just never going to get drugs for certain diseases.”

Source

Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the Best
Created: 11/14/2026, 6:42:06 AM

Your notes

Loading notes...